Dennis Parker, MD
Pulmonary Disease · Okc, OKNPI 1649229097
Payments from drug & device makers
Across 1,415 payments — averaging $32.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$22K
- AstraZeneca$5K
- GSK$3K
- Insmed, Inc.$2K
- Sanofi$1K
- Mylan Specialty L.p.$1K
- plus $12K from 42 others
What the payments were for
- Speaking & faculty fees$18,24040%
- Travel & lodging$1090%
- Food & beverage$27,14859%
- Education$2080%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$1,805
- TEZSPIRE$1,032
- BREZTRI$943
- AIRSUPRA$663
- SYMBICORT$637
- FARXIGA$466
- BREZTRI AEROSPHERE$290
- IMFINZI$259
- CHARTIS CATHETER$158
- ZEPHYR DELIVERY CATHETER$158
- ZEPHYR ENDOBRONCHIAL VALVE$158
- PULMONX CHARTIS TABLET CONSOLE$158
- Monarch Platform$151
- Inspire$140
- TRELEGY ELLIPTA$124
- DUPIXENT$117
How this compares
$45,705 in reported general payments places this provider in the 85th percentile of 133 pulmonary disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 76 | $992,522 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 556 | $503,904 |
| Breo ElliptaFluticasone/Vilanterol | 466 | $247,421 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 217 | $169,043 |
| Fasenra PenBenralizumab | 28 | $165,474 |
| Spiriva RespimatTiotropium Bromide | 116 | $88,402 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 113 | $65,033 |
| Dupixent PenDupilumab | 16 | $59,586 |
| Dupixent SyringeDupilumab | 13 | $48,573 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 85 | $47,717 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 40 | $29,029 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 163 | $26,886 |
| SymbicortBudesonide/Formoterol Fumarate | 73 | $25,917 |
| EliquisApixaban | 25 | $23,673 |
| Arnuity ElliptaFluticasone Furoate | 66 | $20,826 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $21,965 | $1,174,986345 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $2,715 | $819,8681,173 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $5,116 | $205,886312 claims |
| PfizerEliquis | $158 | $23,67325 claims |
| Johnson & JohnsonXarelto | $224 | $19,26520 claims |
| MerckDulera | $217 | $4,99615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 133 pulmonary disease providers in Oklahoma.
Other pulmonary disease in Okc
- Nancy NagleOkc$51K
- John KingreyOklahoma City$2.4M
- Hassan AbouhouliTulsa$2.2M
- Jad KebbeOklahoma City$1.5M
- Michael HullEdmond$743K
- Karen AllenOklahoma City$202K
- Robert GordonOklahoma City$160K
- Jennifer BierachTulsa$141K
- Nicholas ShelburneOklahoma City$102K
- Tony AbdoOklahoma City$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.